{"id":52248,"date":"2025-12-30T16:26:45","date_gmt":"2025-12-30T08:26:45","guid":{"rendered":"https:\/\/flcube.com\/?p=52248"},"modified":"2025-12-30T16:26:46","modified_gmt":"2025-12-30T08:26:46","slug":"buchang-pharmaceuticals-signs-exclusive-malaysia-deal-for-efparepoetin-ckd-anemia-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52248","title":{"rendered":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug"},"content":{"rendered":"\n<p><strong>Buchang Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603858:SHA\">SHA: 603858<\/a>) announced an <strong>Exclusive Supply Agreement<\/strong> with Malaysian firm <strong>Medispec<\/strong> to register, promote, distribute, and sell <strong>Efparepoetin alfa for injection<\/strong> in the target territory, marking Buchang\u2019s <strong>first international partnership<\/strong> for its novel long\u2011acting anemia therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-summary\">Deal Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Efparepoetin alfa for injection<\/td><\/tr><tr><td><strong>Companies<\/strong><\/td><td>Buchang Pharmaceuticals (603858.SH), Medispec (Malaysia)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive Supply Agreement for target territory<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Anemia in adult CKD dialysis patients on erythropoietin therapy<\/td><\/tr><tr><td><strong>Product Class<\/strong><\/td><td>Category\u202f1 biological product (recombinant fusion protein)<\/td><\/tr><tr><td><strong>NDA Status<\/strong><\/td><td>Submitted in China; <strong>no similar products approved domestically<\/strong><\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>First export partnership for Buchang\u2019s biologics platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-efparepoetin-alfa\">Product Profile: Efparepoetin Alfa<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Recombinant fusion protein combining <strong>human erythropoietin (EPO)<\/strong> and <strong>human IgG2 Fc fragment<\/strong><\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Extends half\u2011life via FcRn recycling pathway; reduces injection frequency vs. standard epoetin alfa<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Subcutaneous or intravenous injection for dialysis patients<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong>: <strong>Category\u202f1 biologic<\/strong> NDA submitted; eligible for priority review<\/li>\n\n\n\n<li><strong>Market Exclusivity<\/strong>: <strong>First\u2011in\u2011class<\/strong> in China; patent protection through 2037<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-ckd-anemia-in-southeast-asia\">Market Opportunity: CKD Anemia in Southeast Asia<\/h2>\n\n\n\n<p><strong>Target Territory<\/strong> (Malaysia &amp; potential expansion):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Malaysia dialysis population<\/strong>: ~45,000 CKD patients on hemodialysis (2025)<\/li>\n\n\n\n<li><strong>Anemia prevalence<\/strong>: >90% of dialysis patients require EPO therapy<\/li>\n\n\n\n<li><strong>Current standard<\/strong>: Short\u2011acting epoetin alfa (3x weekly) or IV iron supplementation<\/li>\n\n\n\n<li><strong>Addressable market<\/strong>: <strong>35,000\u201140,000 patients<\/strong> eligible for long\u2011acting EPO therapy<\/li>\n\n\n\n<li><strong>Market value<\/strong>: <strong>RM\u202f180\u2011220\u202fmillion<\/strong> (\u2248\u202fUS$40\u201150\u202fmillion) annually<\/li>\n<\/ul>\n\n\n\n<p><strong>China Market Context<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD patients<\/strong>: \u2248\u202f140\u202fmillion; <strong>dialysis population<\/strong>: 800,000+ and growing at 12% CAGR<\/li>\n\n\n\n<li><strong>EPO market size<\/strong>: <strong>\u00a56.8\u202fbillion<\/strong> (\u2248\u202fUS$950\u202fmillion) in 2025<\/li>\n\n\n\n<li><strong>Unmet need<\/strong>: No long\u2011acting EPO\u2011Fc fusion approved; Efparepoetin poised to capture <strong>15\u201120% market share<\/strong> upon launch<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-terms-amp-strategic-implications\">Commercial Terms &amp; Strategic Implications<\/h2>\n\n\n\n<p><strong>Agreement Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusivity<\/strong>: Medispec holds <strong>exclusive rights<\/strong> for registration and commercialization in target territory<\/li>\n\n\n\n<li><strong>Milestones<\/strong>: Undisclosed upfront payment + regulatory milestones (~US$5\u20118\u202fmillion) + tiered royalties (12\u201115% net sales)<\/li>\n\n\n\n<li><strong>Supply<\/strong>: Buchang to manufacture and supply finished product from its <strong>Chongqing biologics facility<\/strong> (capacity: 2\u202fmillion units\/year)<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong>: Medispec to file marketing authorization application in Malaysia by <strong>Q3\u202f2026<\/strong>, leveraging China NDA data<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Rationale<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>International footprint<\/strong>: Buchang\u2019s <strong>first biologics export<\/strong> validates its manufacturing quality and R&amp;D capabilities<\/li>\n\n\n\n<li><strong>Revenue diversification<\/strong>: Reduces reliance on domestic market; targets <strong>US$50\u202fmillion+<\/strong> peak sales in Southeast Asia by 2030<\/li>\n\n\n\n<li><strong>Platform validation<\/strong>: Establishes template for <strong>future biologics licensing<\/strong> in ASEAN markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manufacturing-amp-supply-chain\">Manufacturing &amp; Supply Chain<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Facility<\/strong>: Buchang\u2019s <strong>state\u2011of\u2011the\u2011art biologics plant<\/strong> in Chongqing (cGMP\u2011certified, 2024)<\/li>\n\n\n\n<li><strong>Capacity<\/strong>: Current line can support <strong>500,000 units\/year<\/strong> for export; scalable to 2\u202fmillion units<\/li>\n\n\n\n<li><strong>Cold Chain<\/strong>: Validated 2\u20118\u00b0C logistics network to Malaysia via regional distribution hub in Singapore<\/li>\n\n\n\n<li><strong>Regulatory Alignment<\/strong>: Manufacturing standards meet both <strong>NMPA<\/strong> and <strong>ASEAN GMP<\/strong> requirements<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding Efparepoetin\u2019s regulatory timeline, market penetration, and revenue potential in Malaysia and Southeast Asia. Actual results may differ materially due to regulatory approvals, competitive responses, and manufacturing scalability challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/603858_20251230_56AX.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603858_20251230_56AX.\"><\/object><a id=\"wp-block-file--media-ef017efa-42fe-443f-8816-034f5ee7c458\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/603858_20251230_56AX.pdf\">603858_20251230_56AX<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/603858_20251230_56AX.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ef017efa-42fe-443f-8816-034f5ee7c458\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52252,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[280,1103],"class_list":["post-52248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-buchang-pharmaceuticals","tag-sha-603858"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register, promote, distribute, and sell Efparepoetin alfa for injection in the target territory, marking Buchang\u2019s first international partnership for its novel long\u2011acting anemia therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52248\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug\" \/>\n<meta property=\"og:description\" content=\"Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register, promote, distribute, and sell Efparepoetin alfa for injection in the target territory, marking Buchang\u2019s first international partnership for its novel long\u2011acting anemia therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52248\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T08:26:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T08:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug\",\"datePublished\":\"2025-12-30T08:26:45+00:00\",\"dateModified\":\"2025-12-30T08:26:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3005.webp\",\"keywords\":[\"Buchang Pharmaceuticals\",\"SHA: 603858\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52248#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52248\",\"name\":\"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3005.webp\",\"datePublished\":\"2025-12-30T08:26:45+00:00\",\"dateModified\":\"2025-12-30T08:26:46+00:00\",\"description\":\"Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register, promote, distribute, and sell Efparepoetin alfa for injection in the target territory, marking Buchang\u2019s first international partnership for its novel long\u2011acting anemia therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52248\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52248#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug - Insight, China&#039;s Pharmaceutical Industry","description":"Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register, promote, distribute, and sell Efparepoetin alfa for injection in the target territory, marking Buchang\u2019s first international partnership for its novel long\u2011acting anemia therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52248","og_locale":"en_US","og_type":"article","og_title":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug","og_description":"Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register, promote, distribute, and sell Efparepoetin alfa for injection in the target territory, marking Buchang\u2019s first international partnership for its novel long\u2011acting anemia therapy.","og_url":"https:\/\/flcube.com\/?p=52248","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-30T08:26:45+00:00","article_modified_time":"2025-12-30T08:26:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52248#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52248"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug","datePublished":"2025-12-30T08:26:45+00:00","dateModified":"2025-12-30T08:26:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52248"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52248#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp","keywords":["Buchang Pharmaceuticals","SHA: 603858"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52248#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52248","url":"https:\/\/flcube.com\/?p=52248","name":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52248#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52248#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp","datePublished":"2025-12-30T08:26:45+00:00","dateModified":"2025-12-30T08:26:46+00:00","description":"Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register, promote, distribute, and sell Efparepoetin alfa for injection in the target territory, marking Buchang\u2019s first international partnership for its novel long\u2011acting anemia therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52248#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52248"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52248#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp","width":1080,"height":608,"caption":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52248#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52248"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52248\/revisions"}],"predecessor-version":[{"id":52253,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52248\/revisions\/52253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52252"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}